Aug 13, 2015 Uncategorized Comments Off on Clinical trials underway for hepatitis B vaccine (China Daily)
A new Cuban-made vaccine against chronic hepatitis B has entered clinical trials in Cuba plus eight countries and regions in Oceania and Asia with the help of French company Abivax.
HeberNasvac, developed by the Cuban Center for Genetic Engineering and Biotechnology in Havana and administered through nasal and subcutaneous injections, is “more effective and safer than the other existing methods in the world” against this illness, Iris Lugo Carro, a specialist in CIGB’s Communication Group, told state daily Granma on Tuesday.
The clinical evaluation studies were approved by regulatory authorities in Australia, New Zealand, South Korea, Singapore, the Philippines, Thailand and China’s Taiwan and Hong Kong, the expert said.
Cuba hopes to start using the vaccine in 2016 after obtaining approval from national health authorities.
Chronic hepatitis is provoked by the hepatitis B virus, which is one of the main causes of liver cancer, cirrhosis and other complications such as esophageal varices.
About 780,000 people die every year from infections caused by this virus, the World Health Organization said.
Cuba’s Health Ministry announced in November that it was working on “highly innovative, safe and efficient” preventive vaccines against cholera, pneumococcus and hepatitis B to be administered this year.
With more than 30 years of experience, Cuban biotechnology has become an important source of income for the Caribbean island.
Cuban medicines are sold to 40 countries all over the world, including China. Medicines sold abroad include vaccines against meningitis and typhoid fever, and treatment for ulcers that has avoided a large number of amputations, Cuban experts said.
(China Daily 08/13/2015 page10)